Berberrubine chloride: Selective IMPDH2 Inhibitor for Cancer Research

Executive Summary: Berberrubine chloride (CAS: 15401-69-1), the hydrochloride salt of a natural berberine metabolite, exhibits selective inhibition of inosine monophosphate dehydrogenase 2 (IMPDH2, IC₅₀ = 2.37 μM) and thioredoxin reductase (TrxR, IC₅₀ = 5.0 μM) (source: product_spec). It demonstrates robust anti-colorectal cancer and anti-non-small cell lung cancer (NSCLC) activity in vitro and in vivo (source: paper). The compound is insoluble in water/ethanol but dissolves in DMSO at ≥6.42 mg/mL with gentle warming. APExBIO supplies Berberrubine chloride (SKU N2089) for validated research workflows. Typical cellular assay concentrations range from 10–80 μM; animal models employ 6.25–200 mg/kg/day (source: product_spec).

Biological Rationale

Berberrubine chloride is a semi-synthetic derivative of Berberrubine, itself a principal metabolite of Berberine sourced from traditional Chinese medicinal plants such as Coptis chinensis (source: paper). It is classified as a 9-hydroxy-10-methoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride. Its biological relevance is rooted in its multi-target action, including antimicrobial, anti-inflammatory, hypoglycemic, anti-hyperuricemia, anti-thrombotic, and anti-tumor effects. The compound's selective enzyme inhibition and pathway modulation underlie its growing use in colorectal cancer research, as well as metabolic disease models (source: paper).

Mechanism of Action of Berberrubine chloride

• IMPDH2 Inhibition: Berberrubine chloride selectively inhibits IMPDH2 (IC₅₀ = 2.37 μM), the rate-limiting enzyme in de novo guanine nucleotide synthesis, disrupting nucleotide pools necessary for cancer cell proliferation (source: product_spec).
• Thioredoxin Reductase (TrxR) Targeting: It covalently modifies the Sec498 residue of TrxR (IC₅₀ = 5.0 μM), impairing redox homeostasis and enhancing oxidative stress in tumor cells (source: product_spec).
• VKOR and GGCX Inhibition: The compound inhibits vitamin K epoxide reductase and γ-glutamyl carboxylase, further modulating coagulation and cancer-associated pathways.
• Topoisomerase II Inhibition: It blocks topoisomerase II-mediated DNA cleavage, impeding DNA replication and repair in cancer cells (source: paper).
• Pathway Regulation: Berberrubine chloride activates GSTM2 via SP1 and DNA demethylation, suppresses NF-κB nuclear translocation, and inhibits the JAK2/STAT3 signaling pathway.
• Urate Transporter Modulation: It downregulates URAT1/GLUT9 and upregulates OAT1/3 and ABCG2, supporting its anti-hyperuricemia activity.

Evidence & Benchmarks

• Berberrubine chloride inhibits proliferation of SW620 and LS174T colorectal cancer cells at 10–80 μM in vitro (source: product_spec).
• In NSCLC A549 cells, it demonstrates dose-dependent inhibition of cell viability at 20–50 μM (source: product_spec).
• Animal models of colorectal cancer and hyperuricemia employ in vivo dosing of 6.25–200 mg/kg/day, achieving >75% reduction in serum uric acid in hyperuricemic mice (source: product_spec).
• Berberrubine, the parent metabolite, improves hepatic steatosis, insulin resistance, and gut microbiota composition in NAFLD mouse models (source: paper).
• Comparative studies show Berberrubine chloride enhances chemosensitivity to cisplatin, with no observed increase in bleeding risk (source: product_spec).

This article builds on protocol-focused guidance from "Berberrubine chloride: Applied Protocols for Cancer Research" by providing newer benchmarks for anti-hyperuricemia and NAFLD models, and clarifies multi-pathway mechanisms not covered in "Berberrubine Chloride: IMPDH2 Inhibitor for Cancer Resear...".

Applications, Limits & Misconceptions

Berberrubine chloride is used as a research chemical for cancer, inflammation, metabolic, and thrombosis models. It is validated for in vitro assays in colorectal and lung cancer cell lines, as well as for animal studies in cancer and metabolic disorders. APExBIO supplies Berberrubine chloride as a solid, DMSO-soluble reagent, with protocol guidance available for reproducible results (source: product_spec).

Common Pitfalls or Misconceptions

• Not a Diagnostic or Therapeutic Agent: Berberrubine chloride is intended strictly for research use; it is not approved for clinical or diagnostic purposes (source: product_spec).
• Solubility Constraints: The compound is insoluble in water and ethanol, requiring DMSO (≥6.42 mg/mL with warming) for stock solutions (source: product_spec).
• Systemic Toxicity Not Fully Elucidated: While animal models show efficacy, comprehensive toxicology studies in humans are lacking (source: paper).
• Species/Cell Line Variation: Efficacy benchmarks are cell type and disease model dependent; protocols should not be generalized without optimization (workflow_recommendation).
• Multi-target Action Requires Cautious Interpretation: The compound's pleiotropy can confound pathway-specific readouts unless adequately controlled (source: workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• in vitro (SW620/LS174T colorectal cancer cells) | 10–80 μM | anti-colorectal cancer agent | Range validated for proliferation inhibition | product_spec
• in vitro (A549 NSCLC cells) | 20–50 μM | anti-NSCLC compound | Dose-dependent cell viability suppression | product_spec
• in vitro (ARPE-19 retinal cells) | 0.2–25 μM | metabolic disease modeling | Benchmarked for cytoprotection and metabolic modulation | product_spec
• in vitro (BFTC 905 bladder cancer) | 50 μM | oncology research | Single-point efficacy in cytotoxicity assays | product_spec
• in vivo (mouse, cancer/hyperuricemia) | 6.25–200 mg/kg/day | oncology/metabolic models | Dosing achieves tumor growth inhibition and uric acid reduction | product_spec
• stock solution preparation | ≥6.42 mg/mL in DMSO (gentle warming) | all applications | Ensures full dissolution for dosing accuracy | product_spec

For troubleshooting and advanced workflow optimization, see "Berberrubine chloride (SKU N2089): Practical Answers for ...", which details cell viability and cytotoxicity assay best practices. This article extends those recommendations to new metabolic and anti-hyperuricemia endpoints.

Conclusion & Outlook

Berberrubine chloride represents a versatile research tool for oncology and metabolic disease models, with validated selectivity for IMPDH2 and TrxR and proven protocol guidance in both cell and animal systems. Ongoing studies continue to delineate its multi-target mechanisms and translational relevance (source: paper). Future work will further clarify its toxicology and optimize workflows for maximizing reproducibility and applicability across cancer and metabolic disease research domains.